Anupam Laul
Optometrist · New York, NYNPI 1114110467
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,140 of the $12,046 with a category attached, or 75.9%. Carl Zeiss Meditec, Inc. accounts for 83.4% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $2,868, more than ten times the $16 reported in 2019. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $273.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$10K
- Alcon$624
- Bausch & Lomb Americas Inc.$543
- Glaukos Corporation$379
- Thea Pharma Inc.$152
- Astellas Pharma US Inc$131
- plus $170 from 3 others
What the payments were for
- Speaking & faculty fees$9,14076%
- Food & beverage$2,83524%
- Education$711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 21 | $10,047 |
| Alcon | 8 | $624 |
| Bausch & Lomb Americas Inc. | 4 | $543 |
| Glaukos Corporation | 5 | $379 |
| Thea Pharma Inc. | 1 | $152 |
| Astellas Pharma US Inc | 1 | $131 |
| Harrow Eye, LLC | 1 | $116 |
| Tarsus Pharmaceuticals, Inc. | 2 | $38 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CIRRUS HD-OCT$9,140
- Humphrey HFA$3,300
- CIRRUS 5000 with AngioPlex$3,200
- CLARUS$2,114
- CIRRUS AngioPlex$2,100
- CIRRUS 6000 with AngioPlex$2,100
- CIRRUS 6000$1,980
- IOLMaster 700$1,980
- Glaucoma Workplace$1,100
- Humphrey FDT$1,100
- CLARUS 500$660
- FORUM Glaucoma Workplace$660
- Rocklatan$250
- VYZULTA$250
- FORUM$230
- CE-marked KXLA system$153
- IYUZEH$152
- MIEBO$147
- XIIDRA$147
- INFUSE$146
How this compares
$12,046 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 44 | $21,017 |
| LumiganBimatoprost | 29 | $18,744 |
| RestasisCyclosporine | 11 | $16,375 |
| RhopressaNetarsudil Mesylate | 19 | $13,003 |
| CombiganBrimonidine Tartrate/Timolol | 33 | $12,905 |
| XiidraLifitegrast | 13 | $9,831 |
| Brimonidine Tartrate | 101 | $8,044 |
| Alphagan PBrimonidine Tartrate | 14 | $5,140 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $3,615 |
| Latanoprost | 309 | $3,452 |
| Brinzolamide | 13 | $3,395 |
| XalatanLatanoprost | 13 | $3,280 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 157 | $2,861 |
| Travoprost | 16 | $2,487 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $1,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $16 | $53,16487 claims |
| Bausch & Lomb Americas Inc.Xiidra | $543 | $9,83113 claims |
| AlconSimbrinza | $624 | $3,61515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in New York
- Susan ResnickNew York$463K
- Denise WhittamNew York$343K
- Jennifer TsaiNew York$275K
- Sophia VisanjiNew York$233K
- Jason ComptonNew York$181K
- Richard MadonnaNew York$75K
- George ZikosNew York$72K
- Craig TischNew York$59K
- Arthur JungNew York$50K
- Milly MuiNew York$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.